Abstract:OBJECTIVE:To compare the incidences of anemia, osteoporosis, and irritable bowel syndrome (IBS) after the application of different endocrine therapies in patients with prostate cancer.METHODS:Totally 125 patients aged 58 to 84 years with biopsy-confirmed local prostate cancer were recruited between September 2008 and September 2010. Of them 52 treated with orchiectomy (castration group) and 73 with luteinizing hormone-releasing hormone analogue (goserelin acetate 3.6mg/month) combined with androgen antagonist (bicalutamide 50mg/d) for at least 12 months (hormone group), but without blood transfusion or erythropoietin. Changes in total testosterone (TT), free testosterone (FT), prostate specific antigen (PSA), hemoglobin (Hb), red blood cell (RBC), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), bone mineral density (BMD) and gastrointestinal symptom rating scales (GSRS) were recorded and analyzed before treatment and 12 months after the initiation of treatment.RESULTS:In the castration group, after 12 months, TT (P=0.0007), FT (P=0.0003), PSA (P=0.0006), Hb (P=0.0001), RBC (P=0.020), Hct (P=0.016), Z-score of lumbar spine (P=0.008), and femoral neck (P=0.004) decreased significantly, and GSRS (P=0.029) increased significantly. In hormone group, after 12 months, TT (P=0.0008), FT (P=0.0006), PSA (P=0.0006), Hb (P=0.0003), RBC (P=0.0001), Hct (P=0.0002), Z-score of lumbar spine (P=0.002), femoral neck (P=0.0002), and RDW (P=0.045) decreased significantly, and GSRS (P=0.010) increased significantly. After 12 months, TT (P=0.004), FT (P=0.012), PSA (P=0.007), Hb (P=0.016), Z-score of lumbar spine (P=0.033), and femoral neck (P=0.015) in hormone group were significantly lower than in the castration group, while GSRS (P=0.027) in hormone group was significantly higher than in the castration group. The incidences of anemia (P=0.006), osteoporosis (P=0.009), and IBS (P=0.022) were significantly different between these two groups. The serum level of testosterone was positively correlated with Hb, RBC, Hct, and BMD in both groups (P=0.039). Negative linear correlations could be seen between serum level of testosterone and GSRS in both groups (P=0.021), and between serum level of testosterone and RDW in medical group only (P=0.044).CONCLUSION:The endocrine therapies, particularly maximal androgen blockage, in patients with prostate cancer can be associated with anemia, osteoporosis, and IBS.

Androgen Replacement Therapy Improves Psychological Distress and Health-Related Quality of Life in Late Onset Hypogonadism Patients in Chinese Population.

Impact of Androgen Replacement on Psychological Condition and Quality of Life in Climacteric Males

Efficacy and Safety of Testosterone Replacement Therapy in Men with Hypogonadism: A Meta-Analysis Study of Placebo-Controlled Trials.

An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate

The Epidemiological Characteristics of Late-Onset Hypogonadism in Chinese Middle-Aged and Elderly Men: Two Cross-Sectional Studies in the Same Community.

Decreased Testosterone Secretion Index and Free Testosterone Level with Multiple Symptoms for Late-Onset Hypogonadism Identification: a Nationwide Multicenter Study with 5980 Aging Males in China.

Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy

Testosterone undecanoate is associated with improved ageing male symptoms score in men with type 2 diabetes and adult-onset testosterone deficiency: re-analyzed results from a randomised controlled trial

Tadalafil Improves Total Testosterone, IIEF Score and SEP in Old and Middle-Aged Males with Late-Onset Hypogonadism

Impact of Hormone Replacement Therapy on the Quality of Life in Climacteric Women

The evaluation of health-related quality of life for prostate cancer patients receiving androgen deprivation therapy

Metabolic Complications and Quality of Life in Prostate Cancer Patients after Receiving Endocrine Treatment

Efficacy and Safety of Degarelix in Patients with Prostate Cancer: Results from a Phase III Study in China

Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study

Clinical treatment of chronic prostatitis patients with depression and testosterone deficiency

Clinical Validation of Screening Scales for Late Onset of Hypogonadism in Chinese Males

The reproductive health indices and sex hormone levels in middle-aged and elderly Chinese men

Association of hypogonadism symptoms and serum hormones in aging males

The Prevalence of Erectile Dysfunction among Subjects with Late-Onset Hypogonadism: a Population-Based Study in China.

Effects of hormone replacement therapy on mood and sleep quality in menopausal women

Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens